Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/30435
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tüzün, Türkan | - |
dc.contributor.author | Sayın Kutlu, Selda | - |
dc.contributor.author | Kutlu, Murat | - |
dc.contributor.author | Kaleli, İlknur | - |
dc.date.accessioned | 2020-06-08T12:13:17Z | |
dc.date.available | 2020-06-08T12:13:17Z | |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1300-0144 | - |
dc.identifier.uri | https://hdl.handle.net/11499/30435 | - |
dc.identifier.uri | https://doi.org/10.3906/sag-1902-24 | - |
dc.description.abstract | Background/aim: Community-onset urinary tract infections (UTIs) caused by extended-spectrum ß-lactamase (ESBL)-producing Escherichia coli have increased in many parts of the world. This study aimed to determine the prevalence and risk factors for community-onset UTI caused by ESBL-producing E. coli. Materials and methods: This prospective cohort study was conducted between January 2012 and March 2014 in cases of community-onset UTI caused by E. coli. Patients with UTI due to ESBL-producing E. coli and patients with UTI due to non-ESBL-producing E. coli were compared to identify risk factors for ESBL-producing E. coli in the community. Results: A total of 305 patients (116 males [46.4%]; mean age: 57.76 ± 18.06 years) were included in the study. Among these patients, 154 (50.5%) were infected with ESBL-producing E. coli. In multivariate analysis, the healthcare-associated UTI (odds ratio [OR]: 1.80; 95% confidence interval [CI]: 1.02–3.18; P = 0.041), upper urinary tract infection (OR: 3.05; 95% CI: 1.76–5.29; P < 0.0001), use of antibiotics in the preceding 6 months (OR: 2.28; 95% CI: 1.21–4.30; P = 0.011), and having two or more risk factors (OR: 4.03; 95% CI: 1.73–9.35; P = 0.001) were the significant factors associated with increased risk of community-onset UTIs due to ESBL-producing E. coli. Conclusion: The increasing prevalence of ESBL-producing E. coli makes it difficult to decide the empirical therapy in UTIs, especially in patients with two or more of the risk factors. A better understanding of the epidemiology and risk factors associated with community-onset UTIs due to ESBL-producing E. coli may have significant implications in decision-making for empirical antimicrobial treatment. © TÜBİTAK. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Turkiye Klinikleri | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Community-onset | en_US |
dc.subject | Epidemiology | en_US |
dc.subject | Extended-spectrum ß-lactamase | en_US |
dc.subject | Risk factors | en_US |
dc.subject | Urinary tract infections | en_US |
dc.subject | amoxicillin plus clavulanic acid | en_US |
dc.subject | antibiotic agent | en_US |
dc.subject | beta lactamase inhibitor | en_US |
dc.subject | cefotaxime | en_US |
dc.subject | ceftazidime | en_US |
dc.subject | cephalosporin | en_US |
dc.subject | ciprofloxacin | en_US |
dc.subject | clavulanic acid | en_US |
dc.subject | extended spectrum beta lactamase | en_US |
dc.subject | fluoroquinolone | en_US |
dc.subject | gentamicin | en_US |
dc.subject | nitrofurantoin | en_US |
dc.subject | piperacillin plus tazobactam | en_US |
dc.subject | quinolone derivative | en_US |
dc.subject | unclassified drug | en_US |
dc.subject | antiinfective agent | en_US |
dc.subject | bacterial protein | en_US |
dc.subject | beta lactamase | en_US |
dc.subject | adolescent | en_US |
dc.subject | adult | en_US |
dc.subject | aged | en_US |
dc.subject | antibiotic sensitivity | en_US |
dc.subject | antimicrobial therapy | en_US |
dc.subject | Article | en_US |
dc.subject | bacterial growth | en_US |
dc.subject | bacterium isolate | en_US |
dc.subject | cohort analysis | en_US |
dc.subject | colony forming unit | en_US |
dc.subject | community | en_US |
dc.subject | community onset urinary tract infection | en_US |
dc.subject | controlled study | en_US |
dc.subject | decision making | en_US |
dc.subject | disk diffusion | en_US |
dc.subject | extended spectrum beta lactamase producing Escherichia coli | en_US |
dc.subject | female | en_US |
dc.subject | healthcare associated infection | en_US |
dc.subject | hospitalization | en_US |
dc.subject | human | en_US |
dc.subject | human versus nonhuman data | en_US |
dc.subject | kidney failure | en_US |
dc.subject | length of stay | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | neoplasm | en_US |
dc.subject | prevalence | en_US |
dc.subject | prospective study | en_US |
dc.subject | risk factor | en_US |
dc.subject | urinalysis | en_US |
dc.subject | urinary tract infection | en_US |
dc.subject | urine culture | en_US |
dc.subject | very elderly | en_US |
dc.subject | community acquired infection | en_US |
dc.subject | drug effect | en_US |
dc.subject | enzymology | en_US |
dc.subject | Escherichia coli | en_US |
dc.subject | Escherichia coli infection | en_US |
dc.subject | microbial sensitivity test | en_US |
dc.subject | microbiology | en_US |
dc.subject | middle aged | en_US |
dc.subject | multidrug resistance | en_US |
dc.subject | pathogenicity | en_US |
dc.subject | Adult | en_US |
dc.subject | Aged | en_US |
dc.subject | Anti-Bacterial Agents | en_US |
dc.subject | Bacterial Proteins | en_US |
dc.subject | beta-Lactamases | en_US |
dc.subject | Community-Acquired Infections | en_US |
dc.subject | Drug Resistance, Multiple, Bacterial | en_US |
dc.subject | Escherichia coli Infections | en_US |
dc.subject | Female | en_US |
dc.subject | Humans | en_US |
dc.subject | Male | en_US |
dc.subject | Microbial Sensitivity Tests | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Prospective Studies | en_US |
dc.subject | Risk Factors | en_US |
dc.subject | Urinary Tract Infections | en_US |
dc.title | Risk factors for community-onset urinary tract infections caused by extended-spectrum ß-lactamase-producing escherichia coli | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 49 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 1206 | |
dc.identifier.startpage | 1206 | en_US |
dc.identifier.endpage | 1211 | en_US |
dc.authorid | 0000-0002-6443-3628 | - |
dc.authorid | 0000-0003-0640-1019 | - |
dc.identifier.doi | 10.3906/sag-1902-24 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.pmid | 31385490 | en_US |
dc.identifier.scopus | 2-s2.0-85071354472 | en_US |
dc.identifier.trdizinid | 336589 | en_US |
dc.identifier.wos | WOS:000480360000035 | en_US |
dc.identifier.scopusquality | Q3 | - |
dc.owner | Pamukkale University | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | open | - |
item.languageiso639-1 | en | - |
item.openairetype | Article | - |
item.fulltext | With Fulltext | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.03. Basic Medical Sciences | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Murat Kutlu.pdf | 226.49 kB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
10
checked on Sep 30, 2024
WEB OF SCIENCETM
Citations
10
checked on Sep 24, 2024
Page view(s)
40
checked on Aug 24, 2024
Download(s)
22
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.